Drug
Triptan
Triptan is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (50.0%)
N/A1 (50.0%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
NCT01086358
completed
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
NCT01435941
withdrawnnot_applicable
The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine
NCT01653522
Clinical Trials (3)
Showing 3 of 3 trials
NCT01086358Phase 4
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
NCT01435941
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
NCT01653522Not Applicable
The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3